Novo Nordisk Surges as JPMorgan Upgrades Sales Forecast for GLP-1 Obesity Drug Pipeline
Novo Nordisk (NVO) stock surged after JPMorgan upgraded its sales forecast for the company’s GLP-1 obesity drug portfolio
Key points
- Novo Nordisk surged after JPMorgan upgraded GLP-1 portfolio sales forecast citing improved coverage and adoption
- JPMorgan revision reflects expanding insurance coverage for Wegovy; Novo competes with Lilly’s tirzepatide
- CMS Medicare coverage decision remains the largest remaining demand catalyst for GLP-1 drugs
What’s your take on this? Join the discussion below.
Read the full analysis on market.news
🇺🇸 United States Stocks Analyst-Upgrade pharma healthcare biotech